BioRestorative Therapies, Inc. (BRTX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -16 | -14 | ||||||
| Net profit | $m | -11 | -44 | -13 | -10 | -9 | -14 | -11 | - |
| EPS reported | $ | -1.58 | -22.20 | ||||||
| Operating cashflow per share | $ | -23.99 | -1.31 | ||||||
| Capex per share | $ | 0.26 | 0.01 | ||||||
| FCF per share | $ | -24.25 | -1.32 | ||||||
| Free cash flow | $m | -11 | -12 | ||||||
| Net debt | $m | -3 | -4 | ||||||
| Book value equity | $m | - | - | ||||||
| Book value per share | $ | 0.79 | 0.34 | ||||||
| Number of shares | m | 8.99 | 0.89 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.01 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 29.75 | 0.44 | ||||||
| P/S LTM | x | 29.50 | 29.65 | ||||||
| P/FCF LTM | x | -0.97 | -0.89 | ||||||
| EV/EBITDA LTM | x | -0.65 | -0.84 | ||||||
| EV/Sales LTM | x | 25.30 | 1.94 | ||||||
| Earnings Yield LTM | % | -1.34% | -8.31% | ||||||
| FCF Yield | % | -102.76% | -112.12% | ||||||
| Quality | |||||||||
| ROE | % | -3992.2% | -423.84% | ||||||
| ROIC | % | -43.86% | -4.65% | ||||||
| Operating margin | % | -43.50% | -39.75% | ||||||
| Gross margin | % | +93.37% | +92.09% | ||||||
| FCF/Sales | % | -3031.7% | -3324.6% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -10.30% | -10.76% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | -0.06% | ||||||
| FCF/Debt | x | - | -344.71 | ||||||
| Net Debt/EBITDA | x | 0.11 | 0.28 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +0.92% | ||||||
| Net debt/Equity | x | - | - | ||||||
| Gross debt/equity | x | - | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BioRestorative Therapies, Inc. (BRTX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free